Showing 6641-6650 of 8649 results for "".
- Visionary Optics New Scleral Lens Design, Europa Tangenthttps://modernod.com/news/visionary-optics-new-scleral-lens-design-europa-tangent/2481375/Visionary Optics announced the launch of Europa Tangent, a scleral lens that combines a customizable design with a streamlined fitting process. The lens design is based on clinical experience and analysis of over 10,000 fittings driven by profilometry data and Visionary Optics’ sc
- Topcon Achieves ISO 27001 Certification of its Harmony RS Clinical Data Management Systemhttps://modernod.com/news/topcon-achieves-iso-27001-certification-of-its-harmony-rs-clinical-data-management-system/2481354/Topcon Healthcare has obtained ISO 27001 certification of its Harmony RS Clinical Data Management System. ISO 27001 is a globally recognized standard for the establishment and certification of an information security management system (ISMS). The standard speci
- Eyenovia: Positive Evidence that Optejet Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Dropshttps://modernod.com/news/eyenovia-positive-evidence-that-optejet-delivery-technology-decreased-inflammation-from-preserved-glaucoma-solutions-compared-to-drops/2481349/Eyenovia announced results from a research study conducted in collaboration with Pedram Hamrah, MD, Interim Chairman of Ophthalmology at Tufts Medical Center, which evaluated the gene and protein expression of cytokines and chemokines after latanoprost+benzalkonium chloride (BAK) treatm
- Oculis Completes Patient Recruitment for Stage 1 of Phase 3 DIAMOND Study Evaluating the Efficacy and Safety of OCS-01 in DMEhttps://modernod.com/news/oculis-completes-patient-recruitment-for-stage-1-of-phase-3-diamond-study-evaluating-the-efficacy-and-safety-of-ocs-01-in-dme/2481323/Oculis announced the completion of enrollment for stage 1 of its phase 3 DIAMOND (DIAbetic Macular edema patients ON a Drop) study evaluating the efficacy and safety of OCS-01 in patients with diabetic macular edema (DME). At the end of 2021, Oculis launched its 2-stage,
- Pixium Vision Completes Implantations in the European Pivotal Trial PRIMAverahttps://modernod.com/news/pixium-vision-completes-implantations-in-the-european-pivotal-trial-primavera/2481297/Pixium Vision SA announced the completion of implantations in all the patients enrolled in the PRIMAvera European pivotal trial in geographic atrophy. A total of 38 patients have been implanted with the Prima System in the PRIMAvera study (NCT04676854), an open-label, baseline
- Staar Surgical Opens EVO Experience Center in United Stateshttps://modernod.com/news/staar-surgical-opens-evo-experience-center-in-united-states/2481249/Staar Surgical announced the opening of the first company-operated EVO Experience Center. The center is located at Staar's corporate headquarters in Lake Forest, California. “We are very excited to open the first company-operated EVO Experience Center for ophthalmic
- EssilorLuxottica Supports New WSPOS Independent Medical Education Program on Myopia Managementhttps://modernod.com/news/essilorluxottica-supports-new-wspos-independent-medical-education-program-on-myopia-management/2481243/EssilorLuxottica announced it is supporting the World Society of Paediatric Ophthalmology and Strabismus (WSPOS) independent medical education program on myopia management, as a gold level supporter, which will be launched on November 19 and 20, at 2-4pm GMT. The key goals of this progr
- Heru Surpasses Clinical Milestone of 100,000 Eyes Examinedhttps://modernod.com/news/heru-surpasses-clinical-milestone-of-100000-eyes-examined/2481242/Heru announced that it has passed the clinical milestone of over 100,000 patient eyes that have been examined using its wearable technology since the company’s commercial launch a little over a year ago. “We are thrilled to see the rapid adoption of the Heru platform,&r
- Opus Genetics Sponsors Uni-Rare Natural History Study for People with Inherited Retinal Diseaseshttps://modernod.com/news/opus-genetics-sponsors-uni-rare-natural-history-study-for-people-with-inherited-retinal-diseases/2481239/Opus Genetics announced the company will co-sponsor the Uni-Rare Study, a new natural history study for approximately 1,500 people with mutations in one of more than 300 rare genes associated with inherited retinal diseases (IRDs). The two-part Uni-Rare Study is being launched to charac
- BioTissue Completes Name Changehttps://modernod.com/news/biotissue-completes-name-change/2481211/BioTissue Holdings announced the completion of its name change from TissueTech. The change is part of a corporate-wide branding initiative launched earlier this year to better represent the company’s entire portfolio and pipeline of products. Pursuant to the name change, the former Tis